Viatris VTRS Japan, Australia and New Zealand Segment — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viatris in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viatris's japan, australia and new zealand segment — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viatris's japan, australia and new zealand segment — net sales?
- Viatris (VTRS) reported japan, australia and new zealand segment — net sales of $273.5M in Q1 2026.
- How has Viatris's japan, australia and new zealand segment — net sales changed year-over-year?
- Viatris's japan, australia and new zealand segment — net sales decreased by 1.3% year-over-year, from $277.1M to $273.5M.
- What is the long-term trend for Viatris's japan, australia and new zealand segment — net sales?
- Over 4 years (2021 to 2025), Viatris's japan, australia and new zealand segment — net sales has grown at a -12.3% compound annual growth rate (CAGR), from $2.03B to $1.2B.
- What does japan, australia and new zealand segment — net sales mean?
- This metric represents the total revenue generated from the sale of pharmaceutical products within the Japan, Australia, and New Zealand geographic region. It reflects the market demand and commercial performance of the company's portfolio in these specific developed markets. Changes in this figure indicate the success of regional sales strategies and local market penetration.